Cullinan Therapeutics, Inc. (CGEM) vs Monte Rosa Therapeutics, Inc. (GLUE)
A side-by-side comparison of Cullinan Therapeutics, Inc. and Monte Rosa Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGEM
Cullinan Therapeutics, Inc.
$16.04HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
GLUE
Monte Rosa Therapeutics, Inc.
$10.27HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CGEM vs GLUE
growth of $100 · dividends reinvested · last 5yCGEM -36.8% (-8.8%/yr)GLUE -51.5% (-13.5%/yr)CGEM compounded faster over this window
CGEM GLUE
CGEM vs GLUE: by the numbers
- •CGEM is the larger company ($986M vs $868M market cap).
- •Both run net losses; CGEM's is the smaller (0.00% vs -560.85% net margin).
Metrics side by side
Valuation
| Metric | CGEM | GLUE |
|---|---|---|
| P/S ratio | N/A | 30.20 |
| P/B ratio | 3.06 | 1.78 |
Profitability
| Metric | CGEM | GLUE |
|---|---|---|
| Gross margin | 0.00% | 92.94% |
| Operating margin | 0.00% | -43.83% |
| Net margin | 0.00% | -560.85% |
| ROE | -63.62% | -33.06% |
| ROIC | -68.64% | -28.69% |
Growth (annualized)
| Metric | CGEM | GLUE |
|---|---|---|
| Total return CAGR (5Y) | -7.48% | -12.32% |
Frequently asked
- How have CGEM and GLUE total returns compared?
- Over the past 5 years, CGEM delivered -7.48% and GLUE delivered -12.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.